Artivion, Inc. (AORT)

Market Cap	1.75B +72.4%
Revenue (ttm)	441.33M +13.6%
Net Income	9.76M
EPS	0.21
Shares Out	48.50M
PE Ratio	172.43
Forward PE	101.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,631
Open	36.09
Previous Close	35.22
Day's Range	35.66 - 36.30
52-Week Range	n/a
Beta	1.62
Analysts	Strong Buy
Price Target	48.76 (+34.81%)
Earnings Date	May 4, 2026

About AORT

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branc...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 1993
• Employees: 1,800
• Stock Exchange: NYSE
• Ticker Symbol: AORT
• Website: https://artivion.com

Analyst Summary

According to 5 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price target is $48.76, which is an increase of 34.81% from the latest price.

Price Target

$48.76

(34.81% upside)

Analyst Consensus: Strong Buy